Literature DB >> 25313914

Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.

Kevin H Maas1, Sandy S Chuan, Heidi Cook-Andersen, H Irene Su, A Duleba, R Jeffrey Chang.   

Abstract

CONTEXT: Women with polycystic ovary syndrome (PCOS) have increased 17-hydroxyprogesterone (17-OHP) responses to gonadotropin stimulation although individual variability is substantial, as reflected by exaggerated as well as normal responses. The relationship between 17-OHP responses to gonadotropin stimulation and markers of ovarian function has not been assessed.
OBJECTIVE: To determine whether 17-OHP responses are associated with antral follicle count (AFC), anti-Mullerian hormone (AMH), or inhibin B (Inh B) levels in PCOS and normal women.
DESIGN: Prospective study.
SETTING: Research center at an academic medical center. PARTICIPANTS: Women with PCOS (n = 18) and normal controls (n = 18).
INTERVENTIONS: Blood samples were obtained before and 24 hours after administration of 25 μg recombinant-human chorionic gonadotropin. Ovarian imaging was conducted with three-dimensional pelvic ultrasound. MAIN OUTCOME MEASURES: Basal and stimulated levels of 17-OHP, androgens, estrogen, AMH, Inh B, and AFC.
RESULTS: In women with PCOS, 17-OHP responses were heterogeneous and inversely correlated with AMH and Inh B levels, but not AFC. In a subgroup of PCOS women with exaggerated 17-OHP responses, AMH levels were equivalent to that of normal women. In PCOS women with normal 17-OHP responses, AMH levels were markedly elevated.
CONCLUSION: Based on heterogeneous 17-OHP responses to human chorionic gonadotropin in women with PCOS, AMH levels are inversely linked to ovarian androgen production while positively correlated with AFC. These findings suggest that in PCOS, AMH production may reflect redistribution of the follicle population or regulation by intraovarian mechanisms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25313914      PMCID: PMC4283019          DOI: 10.1210/jc.2014-2956

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  Follicle-stimulating hormone suppressed excessive production of antimullerian hormone caused by abnormally enhanced promoter activity in polycystic ovary syndrome granulosa cells.

Authors:  Yi Li; Li-Na Wei; Xiao-Yan Liang
Journal:  Fertil Steril       Date:  2011-04-22       Impact factor: 7.329

2.  The role of anti-Müllerian hormone (AMH) during follicle development in a monovulatory species (sheep).

Authors:  Bruce K Campbell; M Clinton; R Webb
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

3.  Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age-matched controls.

Authors:  Michele Brown; Alice S Park; Rana F Shayya; Tanya Wolfson; H Irene Su; R Jeffrey Chang
Journal:  J Magn Reson Imaging       Date:  2013-01-04       Impact factor: 4.813

4.  Differential regulation of ovarian anti-müllerian hormone (AMH) by estradiol through α- and β-estrogen receptors.

Authors:  Michaël Grynberg; Alice Pierre; Rodolfo Rey; Arnaud Leclerc; Nassim Arouche; Laetitia Hesters; Sophie Catteau-Jonard; René Frydman; Jean-Yves Picard; Renato Fanchin; Reiner Veitia; Nathalie di Clemente; Joëlle Taieb
Journal:  J Clin Endocrinol Metab       Date:  2012-06-11       Impact factor: 5.958

5.  Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries.

Authors:  Robert L Rosenfield; Kristen Wroblewski; Vasantha Padmanabhan; Elizabeth Littlejohn; Monica Mortensen; David A Ehrmann
Journal:  Fertil Steril       Date:  2012-04-26       Impact factor: 7.329

6.  Relations between steroids and AMH: impact of basal and intrafollicular steroids to AMH ratios on oocyte yield and maturation rate in women with or without polycystic ovary undergoing in vitro fertilization.

Authors:  Ghamartaj Hossein; Somayeh Arabzadeh; Batool Hossein-Rashidi; Marziyeh Agha Hosseini
Journal:  Gynecol Endocrinol       Date:  2011-10-12       Impact factor: 2.260

7.  Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.

Authors:  Alice Pierre; Maëliss Peigné; Michaël Grynberg; Nassim Arouche; Joëlle Taieb; Laetitia Hesters; Jacques Gonzalès; Jean-Yves Picard; Didier Dewailly; Renato Fanchin; Sophie Catteau-Jonard; Nathalie di Clemente
Journal:  Hum Reprod       Date:  2013-01-14       Impact factor: 6.918

8.  The value of measuring anti-Mullerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy.

Authors:  S A Amer; T C Li; W L Ledger
Journal:  Hum Reprod       Date:  2009-07-29       Impact factor: 6.918

9.  A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mullerian hormone and antral follicle count.

Authors:  L Guzman; C Ortega-Hrepich; N P Polyzos; E Anckaert; G Verheyen; W Coucke; P Devroey; H Tournaye; J Smitz; M De Vos
Journal:  Hum Reprod       Date:  2013-02-20       Impact factor: 6.918

10.  The influence of circulating anti-Müllerian hormone on ovarian responsiveness to ovulation induction with gonadotrophins in women with polycystic ovarian syndrome: a pilot study.

Authors:  Saad A Amer; Ahmad Mahran; Ayman Abdelmaged; Ahmad R El-Adawy; Moustafa K Eissa; Robert W Shaw
Journal:  Reprod Biol Endocrinol       Date:  2013-12-17       Impact factor: 5.211

View more
  7 in total

1.  17-Hydroxyprogesterone responses to human chorionic gonadotropin are not associated with serum anti-Mullerian hormone levels among adolescent girls with polycystic ovary syndrome.

Authors:  Jingwen Hou; Heidi Cook-Andersen; H Irene Su; Rana Shayya; Kevin H Maas; Christine M Burt-Solorzano; Ajay Kumar; R Jeffrey Chang
Journal:  J Pediatr Endocrinol Metab       Date:  2016-07-01       Impact factor: 1.634

2.  Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome.

Authors:  Kevin H Maas; Sandy Chuan; Evan Harrison; Heidi Cook-Andersen; Antoni J Duleba; R Jeffrey Chang
Journal:  Fertil Steril       Date:  2016-07-26       Impact factor: 7.329

3.  A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice.

Authors:  Alexander S Kauffman; Varykina G Thackray; Genevieve E Ryan; Kristen P Tolson; Christine A Glidewell-Kenney; Sheila J Semaan; Matthew C Poling; Nahoko Iwata; Kellie M Breen; Antoni J Duleba; Elisabet Stener-Victorin; Shunichi Shimasaki; Nicholas J Webster; Pamela L Mellon
Journal:  Biol Reprod       Date:  2015-07-22       Impact factor: 4.285

Review 4.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

5.  Individual 17-Hydroxyprogesterone Responses to hCG Are Not Correlated With Follicle Size in Polycystic Ovary Syndrome.

Authors:  Michael V Homer; Tannaz Toloubeydokhti; Mark A Lawson; Gabriel Garzo; Antoni J Duleba; R Jeffrey Chang
Journal:  J Endocr Soc       Date:  2019-02-07

6.  Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach.

Authors:  Lina A Dahabiyeh; Muhammad Mujammami; Reem H AlMalki; Tawfiq Arafat; Hicham Benabdelkamel; Assim A Alfadda; Anas M Abdel Rahman
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

7.  Simultaneous quantitation of four androgens and 17-hydroxyprogesterone in polycystic ovarian syndrome patients by LC-MS/MS.

Authors:  Zheng Cao; Yifan Lu; Yuting Cong; Ying Liu; Youran Li; Husheng Wang; Qiaoli Zhang; Wenxi Huang; Jingrui Liu; Ying Dong; Guodong Tang; Yiqi R Luo; Chenghong Yin; Yanhong Zhai
Journal:  J Clin Lab Anal       Date:  2020-08-21       Impact factor: 3.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.